Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

isatuximab-irfc

View Patient Information
A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab-irfc specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:isatuximab
US brand name:Sarclisa
Code name:Hu 38SB19
SAR 650984
SAR650984
Chemical structure:immunoglobulin G1, anti-(human CD38 antigen) (human-mus musculus monoclonal HU38SB19 heavy chain), disulfide with human-mus musculus monoclonal HU38SB19 light chain, dimer
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search